Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Raptor Pharmaceuticals Stories

2013-05-01 16:31:58

U.S. commercial launch anticipated by end of Q2 2013 NOVATO, Calif., May 1, 2013 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI(TM) (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour...

2013-04-30 16:29:08

U.S. commercial launch anticipated by end of Q2 2013 NOVATO, Calif., April 30, 2013 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI(TM) (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full...

2013-02-28 08:30:04

Drug Company Stocks Stay Strong LONDON, February 28, 2013 /PRNewswire/ -- Markets responded well to Fed chief Ben Bernanke's remarks about the stimulus policy. On the other hand, there are some worries about the ongoing Sequestration debate as well. However, broader indices remained in the green and The Dow Jones closed 1.26% higher at 14,075.37, the S&P 500 closed 1.27% higher at 1,515.99, and the NASDAQ closed 1.04% higher at 3,162.26. Our research team took a look at...

2008-11-13 06:00:36

Raptor Pharmaceuticals, a development-stage biotechnology company, has announced positive results in its Phase IIa study of oral 4-methylpyrazole in subjects with aldehyde dehydrogenase deficiency, or ethanol intolerance, as the initial development stage of its Convivia program. Convivia is Raptor's proprietary oral formulation of 4-methylpyrazole (4-MP) designed to reduce systemic acetaldehyde exposure and related symptoms in aldehyde dehydrogenase (ALDH2) deficient persons following...